Efficacy and safety of camostat mesylate in early COVID-19 disease in an ambulatory setting: a randomized placebo-controlled phase II trial

OBJECTIVES: This study aimed to assess the efficacy and safety of 300 mg camostat mesylate three times daily in a fasted state to treat early phase COVID-19 in an ambulatory setting. METHODS: We conducted a phase II randomized controlled trial in symptomatic (maximum 5 days) and asymptomatic patient...

Descripción completa

Detalles Bibliográficos
Autores principales: Tobback, Els, Degroote, Sophie, Buysse, Sabine, Delesie, Liesbeth, Van Dooren, Lucas, Vanherrewege, Sophie, Barbezange, Cyril, Hutse, Veronik, Romano, Marta, Thomas, Isabelle, Padalko, Elizaveta, Callens, Steven, De Scheerder, Marie-Angélique
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254441/
https://www.ncbi.nlm.nih.gov/pubmed/35803469
http://dx.doi.org/10.1016/j.ijid.2022.06.054

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9254441/
https://www.ncbi.nlm.nih.gov/pubmed/35803469
http://dx.doi.org/10.1016/j.ijid.2022.06.054

Ejemplares similares